Microsoft Word - 内分泌・代謝分野.doc
|
|
|
- ゆめじ やたけ
- 5 years ago
- Views:
Transcription
1 TRH, TRH TSH, a. GH, PRL b.acth, FSH, LH, TSH GH PRL Kallmann KAL LHRH Laurence-Moon-Biedl AR Frohlich
2 Prader-Willi Hypotonia Hypogonadism Hypomentia Obesity Sheehan DIC T4 GH 80% Laron GH IGF-I GH GH acromegaly) GH
3 J-15 GH 10 ng/ml 5 ng/ml double floor ballooning heel pad thickness GH IGF-I -C IGF-I GH GH TRH, GnRH, CRH GH GH GH GH IGF-I P Ca FSH, LH Hardy II Chiari-Frommel Argonz del Castillo Frobes-Albright
4 10 mm MRI T2 10mm, anorexia nervosa 30-20% GH T3 reverse T3 low T3 T.Chol ADH ADH DI; diabetes insipidus)
5 ADH DI MRI T1 DI ADH ADH ADH receptor Ca, Li, K Na Na, Na, SIADH ADH ADH ADH Na K T3, T4, rt3 T3 80% T4 low T3
6 Basedow Af) Stellwag Mobius Grafe TSH C, C,C Chol CK-MM ChE TSH-R R ) R ) ChE ChE Plummer I123- hot nodule
7 C, C, L Chol CK-MM LDH TSA T3, T4 17-OHCS, 17-KS TSH T4 ESR,CRP CRP, ESR
8 CK-MM Chol LDH 70-80% PBC RA, SjS PBC B-42 SjS SS-A, SS-B F-69 T4 R ) Schmidt Addison TSH C
9 CEAMEN2A,2B MEN1 (PPP) Parathyroid, Pituitary, Pancreas MEN2A (PTA) Parathyroid, Thyroid, Adrenal MEN2B (NTA) Nerve, Thyroid, Adrenal 1,2 PPPTA PTA) 1 Ca Ca PTH V.D 3 ) PTH V.D 3 Ca, P PTH Ca P V.D3 Ca P Ca P Ca (ADH ADH Ca Li K Ca, P Ca, P QT Ca PTH camp II RTA PTH HCO3 K, P,Cl
10 K, P II RTA PTH II RTA I RTA I I RTA PTH PTH II RTA I RTA ALP3 MEN I MEN II I HAM HAM PTH Addison Ca PTH Ca, P
11 II ACTH K ACTH ACTH 17-KS 17-OH DHEA 17-OHP DOC 11- OHCS ACTH OHCS I II ACE
12 JG apparatus ADH ACTH, GH Cushing Cushing ACTH microadenoma) Ca Na K K 2mg) Cushing 8mg) 17-OHCS Cushing ACTH MRI/CT
13 17KS ACTH MRI/CT ACTH Cushing CRH ACTH Nelson ACTH ACTH Barter-Gitelman Barter Liddel 17-OHCS, 17-KS Na K Ca K Li K Barter Na-K-2Cl
14 Gitelman Mg Ca Na-Cl Barter Liddel Na Addison Schmidt Addison
15 ACTH Addison Basedow Waterhouse-Friderichsen PC; pheochromocytoma 5H disease: Hypertension Hypermetabolism Hyperglycemia Headache Hyperhydrosis VMA, 17-OHP
16 MEN1 (PPP) Parathyroid, Pituitary, Pancreas MEN2A (PTA) Parathyroid, Thyroid, Adrenal MEN2B (NTA) Nerve, Thyroid, Adrenal 1,2 PPPTA PTA) 1 Zollinger-Ellison Langerhans 80% K Ca PTHMEN1 ZE Wipple's triad 50mg/ml hypervasculr
17 5-20 U/ml triad WDHA Watery Diarrhea, Hypokalemia K, Achlorhydria GHACTH) DM DM
18 DM DM ICA: islet cell antibody GAD 1 DM MODY 75% C-1 20 g/day 200 mg/dl FBS (fasting blood sucrose) 126 mg/dl 75gOGTT (oral glucose tolerance test) 200mg/dl HbA1c 6.5% 75gOGTT HbA1c %) DM DM 25
19 25kcal/kg 30kcal/kg 35 kcal/kg (kcal/day) 1000+(age-1)x kcal FBS>250mg/dl HbA1c>9%) SU BG MODY: maturity-onset diabetes of the young) 25 DM DM DM 1 DM DM DM
20 Kussmaul ph HCO3 BE PCO2 0.9% K K HCO3 GI glucose-insulin K DM 0.45% DKA K K Ca GI Ca
21 330mOsm/l 4ml x (kg) x (%) ml/kg) K
22
23 I, III, IV, VI, VIII II, III, V, VII I von Gierke I, III II Pompe Wilson IV I GAG) Hurler, Hunter, Morquio Hunter Hunter Morquio
24 TG TC: TG: 150 LDL: 160 TC>220, LDL>160, TG>150 CM, VLDL, IDL, LDL, HDL origin, pre-, pre- +, origin, pre =LDL pre V CM, VLDL, IDL, LDL, HDL TG Chol B-100 B-100 B-100 E E E C C A-1 CM VLDL IDL LDL HDL HDL-Chol HDL
25 TC>220, LDL>160, TG>150 HDL 40 R ) TG IIa IIb III IV V I LDL, LDL VLDL, IDL, VLDL, VLDL CM, CM C C,T C,T T T T PBC IIa)IV CM VLDL TG LDL C LDL: VLDL: CM: Friedewald LDL=TC-HDL-1/5TG AIP) -ALAPBG
26 SIADH Wilson AR Kayser-Fleischer Fanconi Wilson D- Menkes Cu Cu Cu Wilson, Menkes, PBC Wilson Cu Cu Menkes Cu Cu PBC Cu Cu 25%) Wilson
27 CT MRI (T2) low PRPP HGPRT de novo salvage de novo PRPP salvage HGPRT 3-7 mg/dl; mg/ml 8 mg/dl Ca ACE Lesch-Nyhan HGPRT
28 J Hz; pill rolling) Wilson base excess (B.E. 0 2 meq/l anion gap (AG) = [Na + ]-([Cl - ] +[HCO 3- ]) 12 2 meq/l [HCO - 3 ] 24 2 meq/l Ca 8-10 mg/dl K4 meq/l
29 AG KUSSMAL K DKA U uremia S S sepsis M A L lactic K K T QRS K T U Ca QT Ca QT K Ca GI Ca Na Na CPM; central pontine myelinolysis) Na Ca Mg Ca hyperventilation ADH Ca, Li, K Ca Na Na DEKA A: D:
30 E: K: II, IX, VII, X B1 Wernicke B2 B6INH B12 C:
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
SC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
III
III 1 1 2 1 2 3 1 3 4 1 3 1 4 1 3 2 4 1 3 3 6 1 4 6 1 4 1 6 1 4 2 8 1 4 3 9 1 5 10 1 5 1 10 1 5 2 12 1 5 3 12 1 5 4 13 1 6 15 2 1 18 2 1 1 18 2 1 2 19 2 2 20 2 3 22 2 3 1 22 2 3 2 24 2 4 25 2 4 1 25 2
iii iv v vi vii viii ix 1 1-1 1-2 1-3 2 2-1 3 3-1 3-2 3-3 3-4 4 4-1 4-2 5 5-1 5-2 5-3 5-4 5-5 5-6 5-7 6 6-1 6-2 6-3 6-4 6-5 6 6-1 6-2 6-3 6-4 6-5 7 7-1 7-2 7-3 7-4 7-5 7-6 7-7 7-8 7-9 7-10 7-11 8 8-1
これわかWord2010_第1部_100710.indd
i 1 1 2 3 6 6 7 8 10 10 11 12 12 12 13 2 15 15 16 17 17 18 19 20 20 21 ii CONTENTS 25 26 26 28 28 29 30 30 31 32 35 35 35 36 37 40 42 44 44 45 46 49 50 50 51 iii 52 52 52 53 55 56 56 57 58 58 60 60 iv
パワポカバー入稿用.indd
i 1 1 2 2 3 3 4 4 4 5 7 8 8 9 9 10 11 13 14 15 16 17 19 ii CONTENTS 2 21 21 22 25 26 32 37 38 39 39 41 41 43 43 43 44 45 46 47 47 49 52 54 56 56 iii 57 59 62 64 64 66 67 68 71 72 72 73 74 74 77 79 81 84
これでわかるAccess2010
i 1 1 1 2 2 2 3 4 4 5 6 7 7 9 10 11 12 13 14 15 17 ii CONTENTS 2 19 19 20 23 24 25 25 26 29 29 31 31 33 35 36 36 39 39 41 44 45 46 48 iii 50 50 52 54 55 57 57 59 61 63 64 66 66 67 70 70 73 74 74 77 77
untitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
平成18年版 男女共同参画白書
i ii iii iv v vi vii viii ix 3 4 5 6 7 8 9 Column 10 11 12 13 14 15 Column 16 17 18 19 20 21 22 23 24 25 26 Column 27 28 29 30 Column 31 32 33 34 35 36 Column 37 Column 38 39 40 Column 41 42 43 44 45
活用ガイド (ソフトウェア編)
ii iii iv NEC Corporation 1998 v vi PA RT 1 vii PA RT 2 viii PA RT 3 PA RT 4 ix P A R T 1 2 3 1 4 5 1 1 2 1 2 3 4 6 1 2 3 4 5 7 1 6 7 8 1 9 1 10 1 2 3 4 5 6 7 8 9 10 11 11 1 12 12 1 13 1 1 14 2 3 4 5 1
untitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
エクセルカバー入稿用.indd
i 1 1 2 3 5 5 6 7 7 8 9 9 10 11 11 11 12 2 13 13 14 15 15 16 17 17 ii CONTENTS 18 18 21 22 22 24 25 26 27 27 28 29 30 31 32 36 37 40 40 42 43 44 44 46 47 48 iii 48 50 51 52 54 55 59 61 62 64 65 66 67 68
A B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
01_.g.r..
I II III IV V VI VII VIII IX X XI I II III IV V I I I II II II I I YS-1 I YS-2 I YS-3 I YS-4 I YS-5 I YS-6 I YS-7 II II YS-1 II YS-2 II YS-3 II YS-4 II YS-5 II YS-6 II YS-7 III III YS-1 III YS-2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
ii iii iv CON T E N T S iii iv v Chapter1 Chapter2 Chapter 1 002 1.1 004 1.2 004 1.2.1 007 1.2.2 009 1.3 009 1.3.1 010 1.3.2 012 1.4 012 1.4.1 014 1.4.2 015 1.5 Chapter3 Chapter4 Chapter5 Chapter6 Chapter7
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
...J......1803.QX
5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299
活用ガイド （ソフトウェア編）
(Windows 95 ) ii iii iv NEC Corporation 1999 v P A R T 1 vi P A R T 2 vii P A R T 3 P A R T 4 viii P A R T 5 ix x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 6 5 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 4
3 5 18 3 5000 1 2 7 8 120 1 9 1954 29 18 12 30 700 4km 1.5 100 50 6 13 5 99 93 34 17 2 2002 04 14 16 6000 12 57 60 1986 55 3 3 3 500 350 4 5 250 18 19 1590 1591 250 100 500 20 800 20 55 3 3 3 18 19 1590
困ったときのQ&A
ii iii iv NEC Corporation 1997 v P A R T 1 vi vii P A R T 2 viii P A R T 3 ix x xi 1P A R T 2 1 3 4 1 5 6 1 7 8 1 9 1 2 3 4 10 1 11 12 1 13 14 1 1 2 15 16 1 2 1 1 2 3 4 5 17 18 1 2 3 1 19 20 1 21 22 1
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
活用ガイド （ソフトウェア編）
(Windows 98 ) ii iii iv v NEC Corporation 1999 vi P A R T 1 P A R T 2 vii P A R T 3 viii P A R T 4 ix P A R T 5 x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 5 6 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 10
i
i ii iii iv v vi vii viii ix x xi ( ) 854.3 700.9 10 200 3,126.9 162.3 100.6 18.3 26.5 5.6/s ( ) ( ) 1949 8 12 () () ア イ ウ ) ) () () () () BC () () (
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
パソコン機能ガイド
PART12 ii iii iv v 1 2 3 4 5 vi vii viii ix P A R T 1 x P A R T 2 xi P A R T 3 xii xiii P A R T 1 2 3 1 4 5 1 6 1 1 2 7 1 2 8 1 9 10 1 11 12 1 13 1 2 3 4 14 1 15 1 2 3 16 4 1 1 2 3 17 18 1 19 20 1 1
パソコン機能ガイド
PART2 iii ii iv v 1 2 3 4 5 vi vii viii ix P A R T 1 x P A R T 2 xi P A R T 3 xii xiii P A R T 1 2 1 3 4 1 5 6 1 2 1 1 2 7 8 9 1 10 1 11 12 1 13 1 2 3 14 4 1 1 2 3 15 16 1 17 1 18 1 1 2 19 20 1 21 1 22
untitled
1998 6 25 ( ) 1 10 1982 10 28 37/7 1990 12 14 45/94 (WHO) 1 1989 12 8 NGO (ECE) 3 1995 10 25 ECE 1991 2 25 1992 3 17 1998 6 4 1 2 1. 2. a b c (a) (b) d 17 3. a b (a) c (b) 4. 5. 3 1. 2. 3. 4. 5. 6. 7.
1... 1 2... 1 1... 1 2... 2 3... 2 4... 4 5... 4 6... 4 7... 22 8... 22 3... 22 1... 22 2... 23 3... 23 4... 24 5... 24 6... 25 7... 31 8... 32 9... 3
3 2620149 3 6 3 2 198812 21/ 198812 21 1 3 4 5 JISJIS X 0208 : 1997 JIS 4 JIS X 0213:2004 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1 2... 1 1... 1 2... 2 3... 2 4... 4 5... 4 6... 4 7... 22
A B C (PP)() B 11 (11p) (S-S) C ()C CPR CPR C peptide immunoreactivity C CPR () () B GLUT TCA ATP - 2 -
A () () () () - 1 - A B C (PP)() B 11 (11p) (S-S) C ()C CPR CPR C peptide immunoreactivity C CPR () () B GLUT TCA ATP - 2 - ATP K (VDCC) Ca () - 3 - GLUT () K 80 () (GIF) GIFGastric inhibitory polypeptide
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
『戦時経済体制の構想と展開』
1 15 15 17 29 36 45 47 48 53 53 54 58 60 70 88 95 95 98 102 107 116 v 121 121 123 124 129 132 142 160 163 163 168 174 183 193 198 205 205 208 212 218 232 237 237 240 247 251 vi 256 268 273 289 293 311
長崎県地域防災計画
i ii iii iv v vi vii viii ix - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - 玢 - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - -
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
™…
i 1 1 1 2 3 5 5 6 7 9 10 11 13 13 14 15 15 16 17 18 20 20 20 21 22 ii CONTENTS 23 24 26 27 2 31 31 32 32 33 34 37 37 38 39 39 40 42 42 43 44 45 48 50 51 51 iii 54 57 58 60 60 62 64 64 67 69 70 iv 70 71
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
1... 1 1... 1 2... 1 3... 1 4... 4 5... 7 6... 7 7... 12 8... 12 9... 13 10... 13 11... 13 12... 14 2... 14 1... 14 2... 16 3... 18 4... 19 5... 19 6.
3 2620149 1 3 8 3 2 198809 1/1 198809 1 1 3 4 5 JISJIS X 0208 : 1997 JIS 4 JIS X 0213:2004 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1 1... 1 2... 1 3... 1 4... 4 5... 7 6... 7 7... 12 8... 12
untitled
I...1 II...2...2 III...3...3...7 IV...15...15...20 V...23...23...24...25 VI...31...31...32...33...40...47 VII...62...62...67 VIII...70 1 2 3 4 m 3 m 3 m 3 m 3 m 3 m 3 5 6 () 17 18 7 () 17 () 17 8 9 ()
活用ガイド （ハードウェア編）
(Windows 98) 808-877675-122-A ii iii iv NEC Corporation 1999 v vi PART 1 vii viii PART 2 PART 3 ix x xi xii P A R T 1 2 1 3 4 1 5 6 1 7 8 1 9 10 11 1 12 1 1 2 3 13 1 2 3 14 4 5 1 15 1 1 16 1 17 18 1 19
i ii iii iv v vi vii viii ix x - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - -
入門ガイド
ii iii iv NEC Corporation 1998 v P A R 1 P A R 2 P A R 3 T T T vi P A R T 4 P A R T 5 P A R T 6 P A R T 7 vii 1P A R T 1 2 2 1 3 1 4 1 1 5 2 3 6 4 1 7 1 2 3 8 1 1 2 3 9 1 2 10 1 1 2 11 3 12 1 2 1 3 4 13
7 i 7 1 2 3 4 5 6 ii 7 8 9 10 11 1 12 13 14 iii.......................................... iv................................................ 21... 1 v 3 6 7 3 vi vii viii ix x xi xii xiii xiv xv 26 27
9 i 9 1 2 3 4 5 6 ii 7 8 9 10 11 12 .......................................... iii ... 1... 1........................................ 9 iv... v 3 8 9 3 vi vii viii ix x xi xii xiii xiv 34 35 22 1 2 1
i ii iii iv v vi vii viii ix x xi xii xiii xiv xv xvi 2 3 4 5 6 7 $ 8 9 10 11 12 13 14 15 16 17 $ $ $ 18 19 $ 20 21 22 23 24 25 26 27 $$ 28 29 30 31 $ $ $ 32 33 34 $ 35 $ 36 $ 37 38 39 40 $ 41 42 43 44
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
困ったときのQ&A
ii iii iv NEC Corporation 1998 v C O N T E N T S PART 1 vi vii viii ix x xi xii PART 2 xiii PART 3 xiv P A R T 1 3 1 2 PART 3 4 2 1 1 2 4 3 PART 1 4 5 5 6 PART 1 7 8 PART 1 9 1 2 3 1 2 3 10 PART 1 1 2
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4
![=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4](/thumbs/91/107033392.jpg "=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4")
1 1 1 1.1 1.1.1 3 : 0: + : +0 : : } 40 40 40 = 3 35 35 (38 )? +0+7 30 35-0+0 38 38 +30 5 30 30 +20 16 16 1. [ ] 2. 3. 4. + = etc 1.1.2 Ru 1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2
3 A 18 11 19 2 1 JIA 2 (JSCA) 3 4 5 6 7 8 9 10 11 12 13 14 B 4 I. (1) 18 3 29 30 33 12 18 3 542,264 22.5 62 46.3 242 149 29% 3 7 7 1 2 1 2 0.1.1 0.1.2 60 17 1 3 6 8 1 2 0.1.3 1 2 0.1.4 5 (2) (1) 0.2.2
SC210301 Ł\†EŒÚ M-KL.ec6
30 36 01 02 07 08 05 95 11 94 11 97 13 91 13 9T 14 15 15 96 16 BE 16 BF 16 BG 17 CL 17 00 17 17 17 1 180 28 28 180 2 180 181 60 180 180 90 32 180 30 15 29 29 30 14 3 15 30 29 29 14 30 14 19 19 30 30 22
（報告書まとめ 2004/03/ ）
- i - ii iii iv v vi vii viii ix x xi 1 Shock G( Invention) (Property rule) (Liability rule) Impact flow 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 (
名称未設定
[ ( 20120719_eng_0211_new2.xml) ] [Class Name] [Super Classes] Any / [Sub Classes (2)] [Description] [ Page - 1 / 41 ] [ ( 20120719_eng_0211_new2.xml) ] [Class Name] [Super Classes] Any / / [Sub Classes
Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
調査報告書
8 15 1 2 3 4 1 2 VTR 3 4 19 19 19 1 2 3 4 5 6-1 - 23 1 2 VTR VTR MA MA 3 2 34 1 BPO - 2 - 2 3 4 5TBS 6 41 1 2 3 4 5 63 1 520 2 3 53 17 4 17 61 17 6 12 69 17 8 7 78 17 10 16 2005 SP 86 17 12 11-3 - 95 18
四校＿目次～巻頭言.indd
107 25 1 2016 3 Key Words : A 114 67 58.84 Mann-Whitney 6 1. 2. 3. 4. 5. 6. I. 21 4 B 23 11 1 9 8 7 23456 108 25 1 2016 3 78 9 II. III. IV. 1. 24 4 A 114 2. 24 5 6 3. 4. 5. 3 42 5 16 6 22 5 4 4 4 3 6.
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
ONLINE_MANUAL
JPN ii iii iv v 6 vi vii viii 1 CHAPTER 1-1 1 2 1-2 1 2 3 4 5 1-3 6 7 1-4 2 CHAPTER 2-1 2-2 2-3 1 2 3 4 5 2-4 6 7 8 2-5 9 10 2-6 11 2-7 1 2 2-8 3 (A) 4 5 6 2-9 1 2-10 2 3 2-11 4 5 2-12 1 2 2-13 3 4 5
ONLINE_MANUAL
JPN ii iii iv v vi 6 vii viii 1 CHAPTER 1-1 1 2 1-2 1 2 3 1-3 4 5 6 7 1-4 2 CHAPTER 2-1 2-2 2-3 1 2 3 4 5 2-4 6 7 8 2-5 9 10 2-6 11 2-7 1 2 2-8 3 (A) 4 5 6 2-9 1 2-10 2 3 2-11 4 5 2-12 1 2 2-13 3 4 5
1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30
1 2420128 1 6 3 2 199103 189/1 1991031891 3 4 5 JISJIS X 0208, 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 3 5 7 6 7
178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21
I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (
untitled
21 + TC : Toatal Choelesterol TGtriglyceride CE : cholesterol ester VLDLvery low density lipoprotein IDLintermediate density lipoprotein LDL low density lipoprotein HDL high density lipoprotein FFAfree
1... 1 2... 3 3... 5 1... 5 2... 6 4... 7 1... 7 2... 9 3... 9 6... 9 7... 11 8... 11 5... 7
3 2620149 1 3 6 3 2 198829 198829 19/2 19 2 3 4 5 JISJIS X 0208 : 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1 2... 3 3... 5 1... 5 2... 6 4... 7 1... 7 2... 9 3... 9 6... 9 7... 11 8...
I
I II III IV V VI VII VIII IX X XI XII XIII XIV 1. 2 3 4 5 2. 6 7 8 3. 1 2 3 9 4 5 10 6 11 4. 1 2 3 1 2 12 1 2 3 1 2 3 13 14 1 2 1 15 16 1. 20 1 21 1 22 23 1 2 3 4 24 1 2 ok 25 1 2 26 1 2 3 27 2. 28
I 12 1 26 4 23 42 1 12 2 12 3 12 4 13 5 13 6 13 7 13 8 14 9 14 10 14 11 14 2 26 3 26 10 27 28 11 28 12 28 13 28 VI 29 1 29 1 29 34 5 35 6 35 7 35 8 35 9 36 10 36 11 36 12 36 1 42 2 42 24 43 25 43 26 43
*: p 慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
2620149 3 8 2 198802 492/ 198802 492 1 4 5 JISJIS X 0208 : 1997 JIS JIS X 0213:2004 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1 1... 1 2... 2 3... 2 4... 2 5... 3 6... 3 7... 4 8... 4 2... 4
LBP-350 ユーザーズガイド
1 3 4 5 6 7 8 i ii viii x xii xii xiii xiv 1 ii 3 4 5 6 9 9 10 1 1 1 13 14 14 15 16 16 18 19 0 1 3 3 4 5 5 6 7 8 8 30 30 31 34 36 4 45 48 51 51 5 54 54 55 56 57 57 57 58 59 60 60 6 64 65 65 66 67 iii 68
Step2 入門
ii iii iv v vi NEC Corporation 1999 vii C O N T E N T S PART 1 PART 2 PART 3 viii PART 4 ix C O N T E N T S PART 5 x PART 6 xi C O N T E N T S PART 7 xii PART 8 PART 9 xiii C O N T E N T S xiv xv PART